Stockscreener 앱 받기
2.97
8.79%
0.24
시간 외 거래:
2.99
0.02
+0.67%
전일 마감가:
$2.73
열려 있는:
$2.77
하루 거래량:
442.19K
Relative Volume:
1.62
시가총액:
$88.68M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-2.2126
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
+1.71%
1개월 성능:
+20.73%
6개월 성능:
+5.69%
1년 성능:
-12.90%
1일 변동 폭
$2.72
$3.0399
1주일 범위
$2.71
$3.0399
52주 변동 폭
$1.90
$3.79
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
VTGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTGN
Vistagen Therapeutics Inc
|
2.97 | 88.68M | 875.70K | -39.57M | -33.65M | -1.3423 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
| 2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-05-20 | 개시 | Robert W. Baird | Outperform |
| 2021-02-18 | 개시 | Jefferies | Buy |
| 2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-06-27 | 개시 | Maxim Group | Buy |
| 2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
| 2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
VistaGen Therapeutics (NASDAQ:VTGN) Releases Quarterly Earnings Results, Meets Estimates - MarketBeat
Vistagen signals Q4 2025 Phase III data readout for fasedienol as pipeline advances - MSN
Vistagen Therapeutics (VTGN) Advances Phase III Trials for Social Anxiety Treatment - GuruFocus
Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid ... - Yahoo Finance
Vistagen Therapeutics Inc (VTGN) Q1 2026 Earnings Call Highlights: Advancing Key Trials Amid Financial Challenges - GuruFocus
Earnings call transcript: VistaGen Therapeutics’ Q1 2025 sees increased R&D costs - Investing.com Nigeria
Earnings call transcript: VistaGen Therapeutics’ Q1 2025 sees increased R&D costs By Investing.com - Investing.com South Africa
Vistagen 2026 Q1 Earnings Widened Losses Despite Surging Revenue - AInvest
Vistagen Therapeutics Reports Progress in Clinical Trials - TipRanks
Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update - BioSpace
Vistagen Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Vistagen (VTGN) Q1 R&D Expense Jumps 54% - Nasdaq
VistaGen Therapeutics (VTGN): Clinical Catalysts and Financial Pressures—Is the Biopharma Still Worth the Gamble? - AInvest
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
VistaGen Therapeutics Inc Q1 Sales Increase - Nasdaq
VistaGen Reports Q1 2026 Financial Results and Update - TipRanks
Vistagen reports Q1 EPS (47c), consensus (44c) - TipRanks
VistaGen Therapeutics: Balancing Burn with Biotech Breakthroughs in a High-Stakes Race - AInvest
Vistagen Therapeutics, Inc. SEC 10-Q Report - TradingView
Biopharmaceutical firm VistaGen Q1 net loss widens - MarketScreener
Market reaction to Vistagen Therapeutics Inc.’s recent newsValue Investing Checklist with Entry Signals - Newser
What makes Vistagen Therapeutics Inc. stock price move sharplyTechnical Chart Summary for Momentum Stocks - Newser
How to track smart money flows in Vistagen Therapeutics Inc.Stock Portfolio Risk and Return Analysis - Newser
Will Vistagen Therapeutics Inc. see short term momentumBuy Zone Strategy with Pattern Recognition - Newser
Is Vistagen Therapeutics Inc. stock a good hedge against inflationDaily Stock Movement Forecast with Accuracy - Newser
Using R and stats models for Vistagen Therapeutics Inc. forecastingMachine Learning Stock Movement Detector - Newser
Using Python tools to backtest Vistagen Therapeutics Inc. strategiesShort Term Gain Strategy with AI Logic - Newser
VistaGen Therapeutics (VTGN) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Vistagen VTGN 2026Q1 Earnings Preview Upside Potential on Neuroscience Pipeline Progress - AInvest
Evaluating Vistagen Therapeutics Inc. with trendline analysisFree Real-Time Analysis With Entry Targets - Newser
Real Time Chart Alerts Flash Bullish on Vistagen Therapeutics Inc.Entry Alert With Low Drawdown Strategy Noted - beatles.ru
Intraday pattern recognizer results for Vistagen Therapeutics Inc.Daily Upside Movement Prediction With Data - Newser
What are analysts’ price targets for Vistagen Therapeutics Inc. in the next 12 monthsOutstanding growth strategies - Jammu Links News
Is it the right time to buy Vistagen Therapeutics Inc. stockRapidly expanding wealth - Jammu Links News
Does Vistagen Therapeutics Inc. stock perform well during market downturnsFree Consultation - Jammu Links News
Should I hold or sell Vistagen Therapeutics Inc. stock in 2025Free Stock Market Trend Analysis - Jammu Links News
Is Vistagen Therapeutics Inc. a growth stock or a value stockConsistently profitable trades - Jammu Links News
What analysts say about Vistagen Therapeutics Inc. stockGet daily updates on promising stocks - Jammu Links News
How many analysts rate Vistagen Therapeutics Inc. as a “Buy”Outstanding capital returns - Jammu Links News
How volatile is Vistagen Therapeutics Inc. stock compared to the marketDiscover market opportunities with expert help - Jammu Links News
When is Vistagen Therapeutics Inc. stock expected to show significant growthMaximize your gains with expert trading tips - Jammu Links News
What institutional investors are buying Vistagen Therapeutics Inc. stockFree Stock Market Knowledge Sharing - jammulinksnews.com
What are the technical indicators suggesting about Vistagen Therapeutics Inc.Build wealth with high-performing stocks - Jammu Links News
Published on: 2025-08-03 02:29:23 - Jammu Links News
Vistagen Therapeutics Inc. Stock Analysis and ForecastFree Popular Stock Recommendations - Jammu Links News
Pattern recognition hints at Vistagen Therapeutics Inc. upsideWeekly Trend Screener with Momentum Picks - Newser
Why Vistagen Therapeutics Inc. stock attracts strong analyst attentionSmart Stock Forecast Using AI Algorithms - Newser
Predicting Vistagen Therapeutics Inc. trend using moving averagesEquity Signal Recap With Long-Term Summary - Newser
Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025 - Barchart.com
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):